Myfembree

Active Ingredient(s): Estradiol + Norethindrone Acetate + Relugolix
FDA Approved: * May 26, 2021
Pharm Company: * MYOVANT SCIENCES
Category: Women's Health / Fertility

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Myfembree Overview

Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand name Myfembree, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.[1][2] It contains relugolix, an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin.[...

Read more Myfembree Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Relugolix/estradiol/norethisterone_acetate

Recent Myfembree Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Estradiol + Norethindrone Acetate + Relugolix
  • Tablet: 1mg + 0.5mg + 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (276 results)